# Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis

> **NCT00534794** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 79 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Elestat
- **DRUG:** Pataday

## Key facts

- **NCT ID:** NCT00534794
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-01
- **Final completion:** —
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2015-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00534794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00534794, "Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00534794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*